April 21, 2023

Raluca Dinu Chief Executive Officer GigCapital5, Inc. 1731 Embarcadero Rd., Suite 200 Palo Alto, CA 94303

Re: GigCapital5, Inc.
Amendment No. 1 to

Registration Statement on Form S-4

2023

Filed April 13,

File No. 333-269760

Dear Raluca Dinu:

 $\label{eq:weak_problem} \mbox{We have reviewed your amended registration statement and have the following}$

comments. In some of our comments, we may ask you to provide us with information so we

may better understand your disclosure.

 $\,$ Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe our comments apply to your facts and

circumstances or do not believe an amendment is appropriate, please tell us why in your $\,$

response.

 $\label{eq:continuous} \mbox{ After reviewing any amendment to your registration statement and the information you}$

provide in response to these comments, we may have additional comments. Unless we note $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

otherwise, our references to prior comments are to comments in our March 14, 2023 letter.

Amendment No.1 to Registration Statement Form S-4 $\,$

Description of the Merger, page 135

1. With reference to the specific guidance within ASC 815, please expand your disclosures identify the terms of the Earnout Shares that cause them to be classified as a liability. In addition, with reference to the specific guidance you relied on, disclose why you have not reflected a pro forma adjustment related to the recognition of these shares.

Other related events in Connection with the Merger, page 138

2. Your response to comment 20 indicates that although no marketing or sales of securities for the PIPE Investment has yet occurred, it is the intent of the Company for such

marketing and sales to

occur prior to the effectiveness of the Registration Statement. You Raluca Dinu

FirstName LastNameRaluca Dinu

GigCapital5, Inc.

Comapany

April NameGigCapital5, Inc.

21, 2023

April 221, 2023 Page 2

Page

FirstName LastName

also indicate that the only result that could satisfy the conditions to the Closing of the $\ensuremath{\mathsf{Closing}}$

Business Combination is one in which there is a PIPE Investment.

Please expand your

disclosures herein to provide this information.

Notes to Unaudited Pro Forma Condensed Combined Financial Statements, page 153

3. We note your expanded disclosures provided in response to comment 17.

As previously

requested, please provide your calculation of the Aggregate Closing Merger Consideration

Value.

- 4. Please include the dilutive Earnout Shares in the table presented on page 158.
- 5. Note (J1) references 586,792 shares for the conversion of certain QT Imaging Convertible

Notes including interest payable. Please reconcile this disclosure to the your table $% \left(1\right) =\left(1\right) +\left(1\right$

presented on page 140 and 141, which indicated total shares issued were 300,920 upon the $\,$

conversion of QT Imaging Convertible Notes. Please expand your disclosures to address

this apparent inconsistency. In this regard, we assume that the 586,792 shares include the

 $242,308\ \mathrm{shares}$ issued in connection with the QT Imaging bridge financing. Ensure the

tables on pages 140 and 141 also include the shares issued for the interest payable and that

the related footnotes appropriately refer to each the convertible notes, bridge financing $% \left(1\right) =\left(1\right) +\left(1\right) +$

and interest payable.

6. On page F-23, you indicated that the Extension Note and the Working Capital Note were

amended subsequent to year end, and the principal amount was increased to \$1,060,000

and \$805,000, respectively. Please expand your pro forma financial information to reflect

these amendments and address the various scenarios related to the conversion/repayment

of these subsequently issued notes and any possible additional notes.

7. Your response to comment 24 indicates neither the QT Imaging Options nor the QT $\,$

Imaging Warrants are being exchanged for shares of GigCapital5 Common Stock.

However, we note your disclosure in your Dear Stockholder Letter and elsewhere that

"...each issued and outstanding share of the common stock of $\mathtt{QT}...\mathtt{including}$ shares issued

upon the exercise or conversion of options to purchase shares of \mathtt{QT} $\mathsf{Imaging}$ Common

Stock that are outstanding as of immediately prior to the Effective Time... [and] warrants

of QT Imaging to purchase QT Imaging Common Stock....will be automatically cancelled

 $% \left(A\right) =\left(A\right) +A\left(A\right) =A\left(A\right) +A\left(A\right) +A$

Consideration $\,$) of common stock..." Please address this apparent inconsistency.

8. We note your response to comment 25 which indicates that the In-the-Money Company

Warrants were defined by Business Combination Agreement to be the QT Imaging

Warrants issued in the bridge financing and a specific list of QT $\operatorname{Imaging}$ Warrants set

forth on the disclosure schedules to the Business Combination Agreement. Please $\,$

disclose the exercise price(s) of these warrants and clarify whether their terms were

modified. If so, (i) discuss the accounting implication of such

modification and (ii) reflect any necessary pro forma adjustments related to the modification.

Reference the authoritative literature you relied on.

Raluca Dinu

FirstName LastNameRaluca Dinu

GigCapital5, Inc.

Comapany

April NameGigCapital5, Inc.

21, 2023

April 321, 2023 Page 3

Page

FirstName LastName

The QT Breast Scanner, page 232

9. We note your revised disclosure on page 235 in response to prior comment 35 that the $\,$

clinical studies were conducted in accordance with the provisions of the Internationa

Conference on Harmonization Guidelines for Good Clinical Practice and

the Declaration

of Helsinki. Please revise to include disclosure of the scope, size and design of the $\ensuremath{\mathsf{S}}$

clinical studies and whether the studies were powered to show statistical significance, as

applicable.

QT Imaging Management's Discussion and Analysis of Financial Condition and Results of Operations , page 275

10. To the extent material, please quantify the impact of each referenced underlying reason

which caused an increase in research and development and general and administrative

expenses for the year ended December 31, 2022 as compared to December 31, 2021.

Background of the Business Combination, page 325

11. We note your response to prior comment 41, which we reissue in part. You disclose that

only one of the ten prospective business combination targets resulted in an executed term $% \left(1\right) =\left(1\right) +\left(1\right) +$

sheet. Please expand your disclosure of the nine potential business combination targets the $\,$

 $\tt GigCapital5$ Board considered and discuss the Board $\tt s$ analysis in reaching its conclusion

not to pursue such targets.

12. We note your response to prior comment 43, which we reissue in part. Please expand

your disclosure of the ten publicly traded companies that were selected with the assistance $% \left(1\right) =\left(1\right) +\left(1\right)$

of Northland Securities. Revise to expand your discussion of the analysis presented to the $\,$

13. Please describe what relationship existed between Wells Fargo and $\operatorname{GigCapital5}$ after the

close of the IPO, including any financial or merger-related advisory services conducted by

Wells Fargo. For example, clarify whether Wells Fargo had any role in the identification $% \left(1\right) =\left(1\right) +\left(1\right) +\left$

or evaluation of business combination targets.

14. Please tell us whether you are aware of any disagreements with Wells Fargo regarding the

disclosure in your registration statement.

15. We note your disclosure on page 113 that Wells Fargo did not provide a reason for the fee

waiver and that you did not engage in any dialogue with them regarding the waiver. If

there was no dialogue and you did not seek out the reasons why Wells Fargo was waiving

deferred fees, despite already completing their services, please indicate so in your

registration statement.

Raluca Dinu

GigCapital5, Inc.

April 21, 2023

Page 4

You may contact Christie Wong at (202) 551-3684 or Jeanne Baker at (202) 551-3691 if

you have questions regarding comments on the financial statements and related matters. Please $\$

contact Jane Park at (202) 551-7439 or Celeste Murphy at (202) 551-3257 with any other

questions.

Sincerely,

Division of

FirstName LastNameRaluca Dinu Corporation Finance

Office of Industrial

Applications and Comapany NameGigCapital5, Inc.

Services

cc: Jeffrey C. Selman, Esq. FirstName LastName